LIN54

Summary

LIN54 (lin-54 DREAM MuvB core complex component, HGNC:25397) is a protein-coding gene on chromosome 4q21.22, encoding Protein lin-54 homolog (Q6MZP7). Component of the DREAM complex, a multiprotein complex that can both act as a transcription activator or repressor depending on the context. It is a selective cancer dependency (DepMap: 24.9% of cell lines).

LIN54 is a component of the LIN, or DREAM, complex, an essential regulator of cell cycle genes (Schmit et al., 2009 [PubMed 19725879]).

Source: NCBI Gene 132660 — RefSeq curated summary.

At a glance

• GWAS associations: 19
• Clinical variants (ClinVar): 70 total
• Cancer dependency (DepMap): dependent in 24.9% of screened cell lines
• MANE Select transcript: NM_194282

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25397
Approved symbol	LIN54
Name	lin-54 DREAM MuvB core complex component
Location	4q21.22
Locus type	gene with protein product
Status	Approved
Aliases	MIP120, DKFZp686L1814, JC8.6, CXCDC1, TCX1
Ensembl gene	ENSG00000189308
Ensembl biotype	protein_coding
OMIM	613367
Entrez	132660

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 20 protein_coding, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000340417, ENST00000442461, ENST00000446851, ENST00000505397, ENST00000505905, ENST00000506560, ENST00000508171, ENST00000509748, ENST00000510557, ENST00000510877, ENST00000857159, ENST00000857160, ENST00000857161, ENST00000857162, ENST00000857163, ENST00000857164, ENST00000924433, ENST00000924434, ENST00000924435, ENST00000924436, ENST00000969090, ENST00000969091, ENST00000969092, ENST00000969093

RefSeq mRNA: 5 — MANE Select: NM_194282 NM_001115007, NM_001115008, NM_001288996, NM_001288997, NM_194282

CCDS: CCDS3599, CCDS47089, CCDS75157

Canonical transcript exons

ENST00000340417 — 13 exons

Exon	Start	End
ENSE00001369618	83010484	83010823
ENSE00001370936	82984161	82984876
ENSE00001375256	82978883	82979006
ENSE00003487395	82946258	82946474
ENSE00003500920	82936279	82936381
ENSE00003536430	82924603	82928303
ENSE00003575706	82930943	82931145
ENSE00003605774	82970327	82970469
ENSE00003631656	82935981	82936118
ENSE00003633302	82939539	82939736
ENSE00003663973	82937227	82937298
ENSE00003675774	82938413	82938504
ENSE00003687611	82939889	82939962

Expression profiles

Bgee: expression breadth ubiquitous, 166 present calls, max score 87.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.3941 / max 292.8685, expressed in 1742 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52902	4.5804	1331
52899	3.2871	1433
52903	1.7456	969
52900	0.6076	308
52901	0.1472	38
52898	0.0262	6

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	87.24	gold quality
bone marrow cell	CL:0002092	86.59	gold quality
calcaneal tendon	UBERON:0003701	85.06	gold quality
ganglionic eminence	UBERON:0004023	83.87	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.75	gold quality
islet of Langerhans	UBERON:0000006	81.32	gold quality
adrenal tissue	UBERON:0018303	81.25	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.73	gold quality
colonic epithelium	UBERON:0000397	79.54	gold quality
stromal cell of endometrium	CL:0002255	79.46	gold quality
lower esophagus mucosa	UBERON:0035834	79.01	gold quality
rectum	UBERON:0001052	78.89	gold quality
cortical plate	UBERON:0005343	78.64	gold quality
hindlimb stylopod muscle	UBERON:0004252	77.16	gold quality
leukocyte	CL:0000738	77.09	gold quality
monocyte	CL:0000576	76.96	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	76.95	gold quality
esophagus mucosa	UBERON:0002469	76.86	gold quality
muscle of leg	UBERON:0001383	76.62	gold quality
gastrocnemius	UBERON:0001388	76.62	gold quality
smooth muscle tissue	UBERON:0001135	76.27	gold quality
vermiform appendix	UBERON:0001154	75.45	gold quality
prefrontal cortex	UBERON:0000451	75.33	gold quality
mucosa of transverse colon	UBERON:0004991	74.11	gold quality
esophagus	UBERON:0001043	74.06	gold quality
Brodmann (1909) area 9	UBERON:0013540	73.92	gold quality
popliteal artery	UBERON:0002250	73.78	gold quality
tibial artery	UBERON:0007610	73.76	gold quality
gall bladder	UBERON:0002110	73.66	gold quality
spinal cord	UBERON:0002240	73.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.18

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F4

miRNA regulators (miRDB)

193 targeting LIN54, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3163	100.00	77.23	8605
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548P	99.98	72.25	3784

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 24.9% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• the cysteine-rich CXC domain of LIN54 is a novel DNA-binding domain that binds to the cdc2 promoter in a sequence-specific manner (PMID:19725879)
• LIN54 harboring a mutation in CHC domain is localized to the cytoplasm and inhibits cell cycle progression. (PMID:22895175)
• the DNA-binding properties of LIN54 and the structural basis for recognition of a cell cycle genes homology region sequence, are described. (PMID:27465258)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lin54	ENSDARG00000063194
mus_musculus	Lin54	ENSMUSG00000118665
rattus_norvegicus	Lin54	ENSRNOG00000002203

Paralogs (1): TESMIN (ENSG00000132749)

Protein

Protein identifiers

Protein lin-54 homolog — Q6MZP7 (reviewed: Q6MZP7)

Alternative names: CXC domain-containing protein 1

All UniProt accessions (2): D6REW4, Q6MZP7

UniProt curated annotations — full annotation on UniProt →

Function. Component of the DREAM complex, a multiprotein complex that can both act as a transcription activator or repressor depending on the context. In G0 phase, the complex binds to more than 800 promoters and is required for repression of E2F target genes. In S phase, the complex selectively binds to the promoters of G2/M genes whose products are required for mitosis and participates in their cell cycle dependent activation. In the complex, acts as a DNA-binding protein that binds the promoter of CDK1 in a sequence-specific manner. Specifically recognizes the consensus motif 5’-TTYRAA-3’ in target DNA.

Subunit / interactions. Component of the DREAM complex (also named LINC complex) at least composed of E2F4, E2F5, LIN9, LIN37, LIN52, LIN54, MYBL1, MYBL2, RBL1, RBL2, RBBP4, TFDP1 and TFDP2. The complex exists in quiescent cells where it represses cell cycle-dependent genes. It dissociates in S phase when LIN9, LIN37, LIN52 and LIN54 form a subcomplex that binds to MYBL2.

Subcellular location. Nucleus.

Domain organisation. The CRC domain mediates DNA-binding. It contains two CXC subdomains (joined by a flexible linker) which are both required for efficient association with target DNA. Each CXC subdomain coordinates three Zn(2+) ions.

Similarity. Belongs to the lin-54 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q6MZP7-1	1	yes
Q6MZP7-2	2
Q6MZP7-3	3
Q6MZP7-4	4
Q6MZP7-5	5

RefSeq proteins (5): NP_001108479, NP_001108480, NP_001275925, NP_001275926, NP_919258* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005172	CRC	Domain
IPR028307	Lin-54_fam	Family
IPR033467	Tesmin/TSO1-like_CXC	Domain

Pfam: PF03638

UniProt features (64 total): binding site 24, modified residue 7, cross-link 5, splice variant 5, helix 5, region of interest 4, mutagenesis site 4, site 3, sequence conflict 2, strand 2, chain 1, domain 1, turn 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5FD3	X-RAY DIFFRACTION	2.42

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6MZP7-F1	53.94	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 536 (critical for interaction with target dna); 574 (interaction with dna); 610 (critical for interaction with target dna)

Ligand- & substrate-binding residues (24): 532; 537; 539; 546; 546; 549; 551; 554; 599; 599; 601; 606 …

Post-translational modifications (12): 244, 249, 264, 282, 310, 314, 635, 139, 357, 639, 659, 661

Mutagenesis-validated functional residues (4):

Position	Phenotype
525	abolishes dna-binding to the cdk1 promoter; when associated with y-527.
527	abolishes dna-binding to the cdk1 promoter; when associated with y-525.
536	loss of dna-binding.
610	loss of dna-binding.

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex
R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
R-HSA-1538133	G0 and Early G1
R-HSA-156711	Polo-like kinase mediated events
R-HSA-69202	Cyclin E associated events during G1/S transition
R-HSA-69205	G1/S-Specific Transcription
R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry
R-HSA-1640170	Cell Cycle
R-HSA-453274	Mitotic G2-G2/M phases
R-HSA-453279	Mitotic G1 phase and G1/S transition
R-HSA-69206	G1/S Transition
R-HSA-69242	S Phase
R-HSA-69275	G2/M Transition
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 193 (showing top): FREAC2_01, REACTOME_G1_S_SPECIFIC_TRANSCRIPTION, TTCCGTT_MIR191, BRN2_01, WTGAAAT_UNKNOWN, OCT1_06, TGACATY_UNKNOWN, NRF2_Q4, CREB_Q3, FISCHER_DREAM_TARGETS, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, CUI_TCF21_TARGETS_2_DN, DBP_Q6, GOBP_CHROMATIN_REMODELING, chr4q21

GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), nucleosome organization (GO:0034728)

GO Molecular Function (5): transcription regulatory region nucleic acid binding (GO:0001067), minor groove of adenine-thymine-rich DNA binding (GO:0003680), metal ion binding (GO:0046872), DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), RNA polymerase II transcription repressor complex (GO:0090571)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Cell Cycle, Mitotic	3
G0 and Early G1	2
Mitotic G1 phase and G1/S transition	2
G1/S Transition	2
G2/M Transition	1
S Phase	1
Mitotic G2-G2/M phases	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid binding	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
chromatin remodeling	1
protein-DNA complex organization	1
DNA secondary structure binding	1
cation binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
transcription repressor complex	1
nuclear protein-containing complex	1

Protein interactions and networks

STRING

1260 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LIN54	LIN37	Q96GY3	999
LIN54	LIN9	Q5TKA1	999
LIN54	RBBP4	P31149	999
LIN54	LIN52	Q52LA3	999
LIN54	MYBL2	P10244	992
LIN54	E2F4	Q16254	943
LIN54	RBL2	Q08999	862
LIN54	FOXM1	Q08050	719
LIN54	MSI1	O43347	665
LIN54	FRG2C	A6NGY1	620
LIN54	RBBP7	Q16576	606
LIN54	E2F5	Q15329	590
LIN54	ZNF354A	O60765	581
LIN54	TIMM8A	O60220	562
LIN54	KCNIP3	Q9Y2W7	541

IntAct

147 interactions, top by confidence:

A	B	Type	Score
PSMC3	PSMD9	psi-mi:“MI:0914”(association)	0.940
CDK2	CCNB2	psi-mi:“MI:0914”(association)	0.860
RBBP4	CDK2AP1	psi-mi:“MI:0914”(association)	0.790
LIN37	RBL2	psi-mi:“MI:0914”(association)	0.770
LIN37	MYBL2	psi-mi:“MI:0914”(association)	0.730
TUSC3	RPN2	psi-mi:“MI:0914”(association)	0.730
L3MBTL2	E2F6	psi-mi:“MI:0914”(association)	0.730
LIN9	MYBL2	psi-mi:“MI:0914”(association)	0.720
LIN9	RBL2	psi-mi:“MI:0914”(association)	0.700
RBL2	LIN9	psi-mi:“MI:0914”(association)	0.700
PSMC3	PSMD12	psi-mi:“MI:0914”(association)	0.640
LIN37	MYBL1	psi-mi:“MI:0914”(association)	0.640
LIN54	RBL2	psi-mi:“MI:0914”(association)	0.620
LIN54	RBL2	psi-mi:“MI:0915”(physical association)	0.620
LIN54	MYBL2	psi-mi:“MI:0914”(association)	0.560
RBL2	LIN52	psi-mi:“MI:0914”(association)	0.560
SF3A2	LIN54	psi-mi:“MI:0915”(physical association)	0.560
SP3	LIN54	psi-mi:“MI:0915”(physical association)	0.560
ZNF143	LIN54	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (156): LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), LIN54 (Proximity Label-MS), LIN54 (Proximity Label-MS), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), MYBL2 (Affinity Capture-Western), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS), LIN54 (Affinity Capture-MS)

ESM2 similar proteins: A1Z9E2, B0R0I6, B5DE69, G5ED89, O94842, P25425, P32519, P34333, P34447, Q02086, Q08CM4, Q09XV5, Q0IHV2, Q0P5K4, Q0V9U1, Q15723, Q28BL7, Q3TUF7, Q571G4, Q5E9U0, Q5F3U0, Q5R6A9, Q5RBN8, Q5RCV7, Q60775, Q641Z1, Q6DJM6, Q6IQU7, Q6MZP7, Q7Z589, Q7ZUV7, Q7ZX03, Q86NP2, Q8AYC1, Q8BIH0, Q8BMB0, Q8BU11, Q8CHI8, Q8IRW8, Q8WNV2

Diamond homologs: A1Z9E2, F4JIF5, F4JY84, Q08CM4, Q0IHV2, Q571G4, Q5RBN8, Q5XHX9, Q641Z1, Q6MZP7, Q700D0, Q84JZ8, Q8L548, Q95QD7, Q9LUI3, Q9SL70, Q9SZD1, Q9WTJ6, Q9Y4I5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 134 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Polo-like kinase mediated events	7	44.0×	2e-08
G0 and Early G1	10	43.5×	6e-12
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	7	41.7×	2e-08
Transcription of E2F targets under negative control by DREAM complex	7	37.7×	4e-08
Cyclin E associated events during G1/S transition	9	25.4×	2e-08
G1/S-Specific Transcription	7	24.7×	9e-07
Cyclin A:Cdk2-associated events at S phase entry	9	23.7×	2e-08
G1/S Transition	6	13.8×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
G1/S transition of mitotic cell cycle	6	9.6×	5e-03
chromatin remodeling	10	5.8×	2e-03
transcription by RNA polymerase II	10	5.6×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2394 predictions. Top by Δscore:

Variant	Effect	Δscore
4:82928138:T:A	donor_gain	1.0000
4:82928161:T:C	donor_gain	1.0000
4:82930937:A:AC	donor_gain	1.0000
4:82930938:C:CC	donor_gain	1.0000
4:82930938:CTTA:C	donor_gain	1.0000
4:82930941:A:AC	donor_gain	1.0000
4:82930941:ACTTT:A	donor_gain	1.0000
4:82930942:C:CG	donor_gain	1.0000
4:82930942:CTTT:C	donor_gain	1.0000
4:82930942:CTTTC:C	donor_gain	1.0000
4:82936274:ATCAC:A	donor_loss	1.0000
4:82936275:TCAC:T	donor_loss	1.0000
4:82936276:CACC:C	donor_loss	1.0000
4:82936278:C:CT	donor_loss	1.0000
4:82936377:AATAC:A	acceptor_gain	1.0000
4:82936378:ATAC:A	acceptor_gain	1.0000
4:82936379:TAC:T	acceptor_gain	1.0000
4:82936380:AC:A	acceptor_gain	1.0000
4:82936381:CC:C	acceptor_gain	1.0000
4:82936381:CCT:C	acceptor_loss	1.0000
4:82936382:C:CC	acceptor_gain	1.0000
4:82936382:CTG:C	acceptor_loss	1.0000
4:82937222:CTTA:C	donor_loss	1.0000
4:82937223:TTACA:T	donor_loss	1.0000
4:82937225:A:AC	donor_gain	1.0000
4:82937225:ACAA:A	donor_loss	1.0000
4:82937226:C:CT	donor_gain	1.0000
4:82937226:CA:C	donor_gain	1.0000
4:82937226:CAA:C	donor_gain	1.0000
4:82937226:CAAT:C	donor_gain	1.0000

AlphaMissense

4821 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:82928184:A:G	L723P	1.000
4:82928187:A:T	I722K	1.000
4:82928239:C:G	A705P	1.000
4:82928250:A:G	L701P	1.000
4:82931038:C:A	R651S	1.000
4:82931038:C:G	R651S	1.000
4:82931048:G:T	A648D	1.000
4:82931049:C:G	A648P	1.000
4:82931052:C:G	A647P	1.000
4:82931058:C:G	A645P	1.000
4:82931060:A:C	L644W	1.000
4:82931060:A:G	L644S	1.000
4:82931069:A:C	L641W	1.000
4:82931069:A:G	L641S	1.000
4:82931077:C:A	R638S	1.000
4:82931077:C:G	R638S	1.000
4:82931086:G:C	S635R	1.000
4:82931086:G:T	S635R	1.000
4:82931088:T:G	S635R	1.000
4:82931098:A:C	N631K	1.000
4:82931098:A:T	N631K	1.000
4:82931099:T:A	N631I	1.000
4:82931099:T:G	N631T	1.000
4:82931100:T:C	N631D	1.000
4:82931100:T:G	N631H	1.000
4:82931104:A:C	C629W	1.000
4:82931105:C:A	C629F	1.000
4:82931105:C:G	C629S	1.000
4:82931105:C:T	C629Y	1.000
4:82931106:A:G	C629R	1.000

dbSNP variants (sampled 300 via entrez): RS10000180 (4:82978611 G>A,T), RS1000037570 (4:82947715 A>C,G), RS1000043824 (4:82972986 C>T), RS1000050755 (4:83003833 T>C), RS1000135675 (4:82987458 T>C), RS1000278599 (4:82935831 G>A,C,T), RS1000282986 (4:82926136 A>G), RS1000288930 (4:82982991 T>C), RS1000325204 (4:82948103 A>G), RS1000348871 (4:82983011 T>G), RS1000387971 (4:82990283 C>T), RS1000454237 (4:82943234 T>C), RS1000456816 (4:82983306 C>A,T), RS1000463919 (4:82932831 A>AT), RS1000537602 (4:82934711 A>G)

Disease associations

OMIM: gene MIM:613367 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST004601_58	Red blood cell count	6.000000e-12
GCST004632_107	Lymphocyte percentage of white cells	1.000000e-09
GCST005996_17	Red blood cell count	8.000000e-09
GCST006629_95	Pulse pressure	4.000000e-14
GCST007267_112	Systolic blood pressure	4.000000e-11
GCST007269_37	Pulse pressure	6.000000e-10
GCST010241_345	Apolipoprotein A1 levels	4.000000e-08
GCST010242_275	HDL cholesterol levels	3.000000e-09
GCST012490_135	Femur bone mineral density x serum urate levels interaction	2.000000e-08
GCST90002383_392	Hematocrit	1.000000e-09
GCST90002388_346	Lymphocyte count	7.000000e-18
GCST90002389_50	Lymphocyte percentage of white cells	3.000000e-17
GCST90002397_12	Mean spheric corpuscular volume	9.000000e-10
GCST90002398_456	Neutrophil count	7.000000e-11
GCST90002399_378	Neutrophil percentage of white cells	3.000000e-10
GCST90002401_147	Platelet distribution width	2.000000e-10
GCST90002403_428	Red blood cell count	1.000000e-18
GCST90002404_82	Red cell distribution width	6.000000e-13
GCST90002407_439	White blood cell count	7.000000e-12

EFO canonical traits (13, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004531	urate measurement
EFO:0004348	hematocrit
EFO:0004587	lymphocyte count
EFO:0004833	neutrophil count
EFO:0007990	neutrophil percentage of leukocytes
EFO:0007984	platelet component distribution width
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	4
Air Pollutants	affects cotreatment, increases abundance, increases expression, decreases expression	2
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
alpha-pinene	increases expression, increases abundance, affects cotreatment	1
arsenite	decreases reaction, affects binding	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
resorcinol	increases expression	1
methacrylaldehyde	increases expression, increases abundance, affects cotreatment	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Leflunomide	increases expression	1
Acrolein	affects cotreatment, increases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Cisplatin	increases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Lipopolysaccharides	affects cotreatment, decreases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	increases expression, increases abundance, affects cotreatment	1
Smoke	increases abundance, decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1
Copper Sulfate	increases expression	1
Acrylamide	increases expression	1
Volatile Organic Compounds	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.